Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protalix BioTherapeutics, Inc. Proxy Solicitation & Information Statement 2023

Jun 28, 2023

33807_rns_2023-06-28_75f05fb9-86f3-4efe-8ea7-713dc04656ab.zip

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

DEFA14A 1 tm2320004d1_defa14a.htm DEFA14A

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

¨ Preliminary Proxy Statement

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨ Definitive Proxy Statement

x Definitive Additional Materials

¨ Soliciting Material Pursuant to §240.14a-12

Protalix BioTherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

¨ Fee paid previously with preliminary materials.

¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Barcode
Shareholder Name
Address 1
Address 2
Address 3

Protalix Biotherapeutics Announces Adjournment of Annual Meeting of Stockholders

Protalix Biotherapeutics. (Ticker: PLX) recently announced that the June 28 th , 2023, Annual Meeting is being adjourned until July 13 th , 2023, to provide stockholders with additional time to vote on Proposal 5, approval of an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock.

Our records indicate your account is currently unvoted.

The Board of Directors as well as leading professional advisory firms ISS and Glass Lewis recommend you FOR Proposal 5.

Proposal 5 requires an affirmative vote of 50% of the outstanding shares for passage. By not responding with your vote, you are essentially opposing this proposal. Therefore, we urge our stockholders who have not yet executed their vote to please do so. This will help save on further solicitation costs and ensure that your important vote is represented.

Please vote your shares of stock now so that your vote can be counted without delay. If you have any questions or require assistance in voting your shares, please contact our proxy solicitor Alliance Advisors toll-free at +1 (855) 200- 7892 or email [email protected] .

If you wish to vote electronically online you can scan the QR code below:

Insert QR CODE HERE

Sincerely,

Gina Balderas

Operations Manager

IF YOU HAVE RECENTLY VOTED PLEASE ACCEPT OUR THANKS AND DISREGARD THIS REQUEST.

Field: Page; Sequence: 2; Options: Last

Field: /Page